An investigation on behalf of investors in I-Mab (NASDAQ:IMAB) shares over potential wrongdoing at I-Mab was announced.
San Diego, CA -- (SBWIRE) -- 10/20/2022 -- An investigation was announced for current long-term investors in shares of I-Mab (NASDAQ: IMAB) over potential breaches of fiduciary duties by certain directors at I-Mab .
Investors who purchased shares of I-Mab (NASDAQ: IMAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain I-Mab directors breached their fiduciary duties and caused damage to the company and its shareholders.
China based I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders.
On or around January 17, 2020, I-Mab conducted its initial public offering ("IPO"), selling more than 7 million ADSs priced at $14.00 per ADS.
On August 16, 2022, I-Mab disclosed in a filing with the U.S. Securities and Exchange Commission that its collaboration partner "AbbVie will discontinue the global Phase 1b study of [I-Mab's] lemzoparlimab combination therapy with azacitidine ('AZA') and venetoclax, in patients with myelodysplastic syndrome ('MDS') and acute myelocytic leukemia ('AML')."
Shares of I-Mab (NASDAQ: IMAB) declined to as low as $3.30 per share on October 11, 2022.
Those who purchased shares of I-Mab (NASDAQ: IMAB) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.